Autonomix Medical, Inc. R&D

Autonomix Medical, Inc. R&D, located at 242 Wood Street in Doylestown, Pennsylvania, is a cutting-edge institution focused on developing innovative technology in the field of electrophysiology. Our two-fold technology aims to detect malfunctioning neural signals and ablate nerves in a single procedure for effective pain management. Clinical trials are set to begin this year for the treatment of pancreatic cancer pain and pancreatitis pain.

As a rapidly growing market, the field of electrophysiology offers exciting new opportunities for advancements in medical treatment. Autonomix is poised to be a major player in this field, with a strong focus on developing technology that can revolutionize the lives of patients suffering from various medical conditions.

Recent milestones include the successful completion of an $11.2 million initial public offering, as well as the formation of an engineering development team to drive project advancements. Additionally, the appointment of Christopher C. Capelli, M.D. to the Board of Directors further strengthens our leadership team.

Please note that this presentation is for informational purposes only and should not be reproduced without prior consent from Autonomix. Forward-looking statements may be included, and interested parties are encouraged to carefully review all information provided before making any investment decisions.

For more information on Autonomix Medical, Inc. R&D and our groundbreaking research in electrophysiology, please visit our website or contact us directly. Thank you for your interest in our work.